Cilostazol's Protective Effect Against Diabetic Retinopathy in Rats
Author Information
Author(s): Diego José Schebelski, Leandro Lipinski, Carlos Augusto Moreira Junior, Adriana Yuriko Koga, Bruna Carletto, Mario M. Montemor, Paulo Vitor Farago, Ricardo Zanetti Gomes
Primary Institution: Universidade Estadual de Ponta Grossa
Hypothesis
Does cilostazol protect against the development and progression of diabetic retinopathy in rats?
Conclusion
Cilostazol protects against changes caused by diabetic retinopathy in diabetic rats by reducing ganglion cell loss and sensorineural atrophy.
Supporting Evidence
- The cilostazol-treated nondiabetic rats had a significantly higher mean nuclei count in the inner nuclear layer and inner plexiform layer compared to other groups.
- The total mean retinal thickness of cilostazol-treated nondiabetic rats was significantly higher than that of cilostazol-treated diabetic rats and untreated diabetic rats.
- The number of nuclei in the ganglion cell layer was significantly higher in untreated nondiabetic rats.
Takeaway
Cilostazol helps protect the eyes of diabetic rats from damage, keeping more of their important cells healthy.
Methodology
Sixty male rats were divided into four groups to assess the effects of cilostazol on diabetic retinopathy, measuring retinal layer thickness and cell counts.
Limitations
The study was conducted on a specific rat model, which may not fully represent human diabetic retinopathy.
Participant Demographics
Sixty male Wistar rats, aged 90 days.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website